Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peregrine Pharmaceuticals
To confirm the safety and tolerability of the Maximum Tolerated Dose (MTD) of 131I-chTNT-1/B MAb given as a single interstitial infusion in patients with glioblastoma multiforme at first relapse.
To estimate overall survival, progression free survival and proportion of patients alive at six months after treatment.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed GBM
Clinical Target Volume between 5 and 60 cc (inclusive)
18 to 75 years old (inclusive)
Karnofsky Performance Status ≥ 70 percent
If on steroids dose (± 4mg/day) must be stable for at least two weeks prior to screening/baseline visit. If not on steroids for two weeks prior to screening/baseline visit are allowed
Adequate hematology
Adequate renal function
Adequate liver function
You may not be if
Infratentorial tumor(s), tumor(s) that communicate with the ventricles or intraventricular disease
